Cargando…
MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy
Recent estimates suggest that 1 in 12 of the global population suffers from diabetes mellitus. Approximately 40 % of those affected will go on to develop diabetes-related chronic kidney disease or diabetic nephropathy (DN). DN is a major cause of disability and premature death. Existing tests for pr...
Autores principales: | Simpson, Kate, Wonnacott, Alexa, Fraser, Donald J., Bowen, Timothy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791477/ https://www.ncbi.nlm.nih.gov/pubmed/26973290 http://dx.doi.org/10.1007/s11892-016-0724-8 |
Ejemplares similares
-
An Update on the Use of Animal Models in Diabetic Nephropathy Research
por: Betz, Boris, et al.
Publicado: (2016) -
Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony
por: Yeung, Stanley M. H., et al.
Publicado: (2020) -
Harnessing Metabolomics to Describe the Pathophysiology Underlying Progression in Diabetic Kidney Disease
por: Hasegawa, Sho, et al.
Publicado: (2021) -
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
por: Bailey, Clifford J., et al.
Publicado: (2022) -
New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
por: Dekkers, Claire C. J., et al.
Publicado: (2018)